1型干扰素预防异基因移植后白血病复发
该1/2期临床试验在高危急性髓系白血病(AML)患者中,于异基因造血干细胞移植(HCT)围移植期给予长效干扰素α(pegIFNα),采用自适应设计确定最大耐受剂量(MTD)为180 μg。移植后6个月复发率为39%,持续至1年;移植相关死亡率为13%,III-IV级急性移植物抗宿主病(GVHD)发生率为11%。
要点
- pegIFNα在高危AML围移植期可安全给予,MTD为180 μg。
- 移植后6个月复发率为39%,1年内维持该水平。
- 未观察到超预期毒性,初步提示可能降低移植后复发。
核心结论
- 在高危AML患者中,围移植期预防性给予pegIFNα可行,未增加毒性,并有初步证据提示可降低移植后白血病复发。
主要发现
- 25%的患者发生≥3级严重不良事件,确定180 μg为MTD。
- 2期阶段移植后6个月复发率为39%,并持续至移植后1年。
- 移植相关死亡率为13%,III-IV级急性GVHD发生率为11%。
- 移植后供受者配对血样显示1型IFN水平升高伴细胞反应、交叉呈递树突状细胞持续存在及循环白血病抗原特异性T细胞。
关键数值与推荐
- MTD为180 μg;6个月复发率39%;移植相关死亡率13%;III-IV级急性GVHD发生率11%。
临床怎么用
- 对于治疗抵抗未缓解或不良风险白血病的高危AML患者,可考虑在围移植期预防性使用pegIFNα,但需进一步验证疗效。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A potent graft-versus-leukemia (GVL) response is crucial in preventing relapse, the major impediment to successful allogeneic hematopoietic cell transplantation (HCT). In preclinical studies, type 1 interferon (IFN-α) enhanced cross-presentation of leukemia-specific antigens by CD8α dendritic cells (DCs) and amplified GVL. This observation was translated into a proof-of-concept phase 1/2 clinical trial with long-acting IFN-α (pegylated IFN-α [pegIFNα]) in patients undergoing HCT for high-risk acute myeloid leukemia (AML). Patients with treatment-resistant AML not in remission or those with poor-risk leukemia were administered 4 dosages of pegIFNα every 14 days beginning at day -1 before HCT. Dose selection was established by adaptive design that continuously assessed the probability of dose-limiting toxicities throughout the trial. Efficacy was evaluated by determining the 6-month incidence of relapse at the maximum tolerated dose (MTD). Thirty-six patients (median age, 60 years) received pegIFNα treatment. Grade 3 or greater severe adverse events occurred in 25% of patients, establishing 180 μg as the MTD. In phase 2, the incidence of relapse was 39% at 6 months, which was sustained through 1-year post-HCT. The incidence of transplant-related mortality was 13%, and severe grade III-IV acute graft-versus-host disease (GVHD) occurred in 11%. Paired blood samples from donors and recipients after HCT revealed elevated levels of type 1 IFN with cellular response, the persistence of cross-presenting DCs, and circulating leukemia antigen-specific T cells. These data suggest that prophylactic administration of pegIFNα is feasible in the peri-HCT period. In high-risk AML, increased toxicity was not observed with preliminary evidence for reduction in leukemia relapse after HCT. This trial was registered at www.clinicaltrials.gov as #NCT02328755.
引用
- Magenau JM, Peltier D, Riwes M, et al. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021. PMID: 34607341. doi:10.1182/bloodadvances.2021004908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。